Precision, complexity and stigma in advanced prostate cancer terminology: It is time to move away from 'castration-resistant' prostate cancer

ANZUP Consumer Advisory Panel

doi:10.1093/annonc/mdx312

Precision, complexity and stigma in advanced prostate cancer terminology: It is time to move away from 'castration-resistant' prostate cancer

ANZUP Consumer Advisory Panel

Medicine - Hematology, Oncology, Transplant

Research output: Contribution to journal › Editorial › peer-review

6 Scopus citations

Original language	English (US)
Pages (from-to)	1692-1694
Number of pages	3
Journal	Annals of Oncology
Volume	28
Issue number	8
DOIs	https://doi.org/10.1093/annonc/mdx312
State	Published - Aug 1 2017

Bibliographical note

Funding Information:
CP: advisory boards (compensated): Novartis. Honoraria: Janssen, Pfizer, Sanofi, Novartis, Astellas. Travel support: Pfizer, Sanofi, Amgen. AO: advisory boards (compensated, institutional): Bayer, Astellas, Janssen, Sanofi, Pfizer. Travel support: Bayer, Astellas, Janssen, Sanofi. Research support (institutional): Janssen, Teva. FS: advisory boards, honoraria and research: Amgen, Astellas. Bayer, Janssen, Sanofi, Takeda. SG: advisory boards: AAA, Astellas, Bayer, Curevac, Dendreon, Janssen Cilag, Janssen Diagnostics, Millennium, Novartis, Orion Pharma, Pfizer, Sanofi Aventis. Advisory Boards (uncompensated): ProteoMediX, ESSA Pharmaceuticals Corp. Speakers Bureau (without personal honorarium): Amgen, Astellas, Bayer, Janssen Cilag, Novartis, Sanofi Aventis. IDD is supported by an NHMRC Practitioner Fellowship (APP1102604).

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1093/annonc/mdx312

Find It

Find It at U of M Libraries

Cite this

@article{f91b3763f5f743138151b5493403780d,

title = "Precision, complexity and stigma in advanced prostate cancer terminology: It is time to move away from 'castration-resistant' prostate cancer",

author = "{ANZUP Consumer Advisory Panel} and Pezaro, {C. J.} and A. Omlin and K. Mastris and G. Attard and Beer, {T. M.} and Chi, {K. N.} and S. Chowdhury and Davis, {I. D.} and Drake, {C. G.} and {de Bono}, {J. S.} and E. Efstathiou and G. Gravis and Higano, {C. S.} and M. Hussain and N. James and Logothetis, {C. J.} and A. Morgans and C. Parker and Ryan, {C. J.} and F. Saad and O. Sartor and Small, {E. J.} and Sternberg, {C. N.} and Sweeney, {C. J.} and I. Tannock and B. Tombal and S. Gillessen",

note = "Funding Information: CP: advisory boards (compensated): Novartis. Honoraria: Janssen, Pfizer, Sanofi, Novartis, Astellas. Travel support: Pfizer, Sanofi, Amgen. AO: advisory boards (compensated, institutional): Bayer, Astellas, Janssen, Sanofi, Pfizer. Travel support: Bayer, Astellas, Janssen, Sanofi. Research support (institutional): Janssen, Teva. FS: advisory boards, honoraria and research: Amgen, Astellas. Bayer, Janssen, Sanofi, Takeda. SG: advisory boards: AAA, Astellas, Bayer, Curevac, Dendreon, Janssen Cilag, Janssen Diagnostics, Millennium, Novartis, Orion Pharma, Pfizer, Sanofi Aventis. Advisory Boards (uncompensated): ProteoMediX, ESSA Pharmaceuticals Corp. Speakers Bureau (without personal honorarium): Amgen, Astellas, Bayer, Janssen Cilag, Novartis, Sanofi Aventis. IDD is supported by an NHMRC Practitioner Fellowship (APP1102604).",

year = "2017",

month = aug,

day = "1",

doi = "10.1093/annonc/mdx312",

language = "English (US)",

volume = "28",

pages = "1692--1694",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd",

number = "8",

}

TY - JOUR

T1 - Precision, complexity and stigma in advanced prostate cancer terminology

T2 - It is time to move away from 'castration-resistant' prostate cancer

AU - ANZUP Consumer Advisory Panel

AU - Pezaro, C. J.

AU - Omlin, A.

AU - Mastris, K.

AU - Attard, G.

AU - Beer, T. M.

AU - Chi, K. N.

AU - Chowdhury, S.

AU - Davis, I. D.

AU - Drake, C. G.

AU - de Bono, J. S.

AU - Efstathiou, E.

AU - Gravis, G.

AU - Higano, C. S.

AU - Hussain, M.

AU - James, N.

AU - Logothetis, C. J.

AU - Morgans, A.

AU - Parker, C.

AU - Ryan, C. J.

AU - Saad, F.

AU - Sartor, O.

AU - Small, E. J.

AU - Sternberg, C. N.

AU - Sweeney, C. J.

AU - Tannock, I.

AU - Tombal, B.

AU - Gillessen, S.

N1 - Funding Information: CP: advisory boards (compensated): Novartis. Honoraria: Janssen, Pfizer, Sanofi, Novartis, Astellas. Travel support: Pfizer, Sanofi, Amgen. AO: advisory boards (compensated, institutional): Bayer, Astellas, Janssen, Sanofi, Pfizer. Travel support: Bayer, Astellas, Janssen, Sanofi. Research support (institutional): Janssen, Teva. FS: advisory boards, honoraria and research: Amgen, Astellas. Bayer, Janssen, Sanofi, Takeda. SG: advisory boards: AAA, Astellas, Bayer, Curevac, Dendreon, Janssen Cilag, Janssen Diagnostics, Millennium, Novartis, Orion Pharma, Pfizer, Sanofi Aventis. Advisory Boards (uncompensated): ProteoMediX, ESSA Pharmaceuticals Corp. Speakers Bureau (without personal honorarium): Amgen, Astellas, Bayer, Janssen Cilag, Novartis, Sanofi Aventis. IDD is supported by an NHMRC Practitioner Fellowship (APP1102604).

PY - 2017/8/1

Y1 - 2017/8/1

UR - http://www.scopus.com/inward/record.url?scp=85029301441&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029301441&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdx312

DO - 10.1093/annonc/mdx312

M3 - Editorial

C2 - 28838209

AN - SCOPUS:85029301441

SN - 0923-7534

VL - 28

SP - 1692

EP - 1694

JO - Annals of Oncology

JF - Annals of Oncology

IS - 8

ER -

Precision, complexity and stigma in advanced prostate cancer terminology: It is time to move away from 'castration-resistant' prostate cancer

Bibliographical note

UN SDGs

Publisher link

Find It

Other files and links

Cite this